Gate Bioscience website screenshot

Gate Bioscience

Gate Bioscience is a preclinical biotechnology company founded in 2021 and headquartered in Brisbane, California, creating a new class of small-molecule medicines called Molecular Gates. Molecular Gates selectively eliminate disease-causing extracellular proteins at their origin inside the cell by binding the secretory translocon, the channel through which proteins exit the cell, so targeted proteins are degraded rather than secreted. The company's proprietary Molecular Gate Discovery Platform pairs a privileged library of molecules with bespoke secretion-focused assays and deep secretory-pathway biology to pursue more than 1,000 diseases linked to extracellular proteins. Gate Bioscience is backed by Andreessen Horowitz (a16z) Bio + Health, GV, Versant Ventures, ARCH Venture Partners, Forbion and Eli Lilly, and has raised roughly $134M across Series A and an oversubscribed $65M Series B. As a therapeutics company it publishes no public developer API, portal, or documentation; this profile is an API Evangelist network company record maintained for the portfolio graph.

Gate Bioscience is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Life Sciences.

Gate Bioscience’s developer surface includes engineering blog and 2 more developer resources.

🌐 Visit website 📡 Source on GitHub
8.1/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyPharmaceuticalsDrug DiscoveryLife SciencesTherapeuticsMolecular Biology

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 8.1/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.4 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/gate-bioscience: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Gate Bioscience Domain Security

TLSv1.3 · HSTS

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 2

The organization behind the API

Website
Website
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: gate-bioscience
name: Gate Bioscience
description: Gate Bioscience is a preclinical biotechnology company founded in 2021 and headquartered in Brisbane, California,
  creating a new class of small-molecule medicines called Molecular Gates. Molecular Gates selectively eliminate disease-causing
  extracellular proteins at their origin inside the cell by binding the secretory translocon, the channel through which proteins
  exit the cell, so targeted proteins are degraded rather than secreted. The company's proprietary Molecular Gate Discovery
  Platform pairs a privileged library of molecules with bespoke secretion-focused assays and deep secretory-pathway biology
  to pursue more than 1,000 diseases linked to extracellular proteins. Gate Bioscience is backed by Andreessen Horowitz (a16z)
  Bio + Health, GV, Versant Ventures, ARCH Venture Partners, Forbion and Eli Lilly, and has raised roughly $134M across Series
  A and an oversubscribed $65M Series B. As a therapeutics company it publishes no public developer API, portal, or documentation;
  this profile is an API Evangelist network company record maintained for the portfolio graph.
url: https://raw.githubusercontent.com/api-evangelist/gate-bioscience/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
- gv
x-tier: stub
x-tier-reason: no-public-api-surface
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
image: https://cdn.prod.website-files.com/651ef47f48428a3c2cd4108a/654c13fb532c4467e354569b_1005.svg
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Life Sciences
- Therapeutics
- Molecular Biology
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.gatebio.com
- type: Blog
  url: https://www.gatebio.com/news
- type: DomainSecurity
  url: security/gate-bioscience-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence